🚀 VC round data is live in beta, check it out!
Nkarta Valuation Multiples
Discover revenue and EBITDA valuation multiples for Nkarta and similar public comparables like CHO Pharma, Karyopharm Therapeutics, Savior Lifetec, PhotoCure and more.
Nkarta Overview
About Nkarta
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
Founded
2015
HQ
Employees
157
Website
Sectors
Financials (LTM)
Market Cap
$175M
Nkarta Financials
Nkarta reported last 12-month revenue of —.
In the same LTM period, Nkarta generated — in gross profit and had net loss of ($99M).
Revenue (LTM)
Nkarta P&L
In the most recent fiscal year, Nkarta reported revenue of — and EBITDA of ($119M).
Nkarta expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($119M) | XXX | XXX | XXX |
| Net Profit | ($99M) | XXX | ($109M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Nkarta Stock Performance
Nkarta has current market cap of $175M.
Market Cap Evolution
Nkarta's stock price is $2.47.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $175M | 0.0% | XXX | XXX | XXX | $-1.53 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNkarta Valuation Multiples
Nkarta trades at 0.3x EV/EBITDA.
Nkarta Financial Valuation Multiples
As of March 18, 2026, Nkarta has market cap of $175M.
Equity research analysts estimate Nkarta's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nkarta has a P/E ratio of (1.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $175M | XXX | $175M | XXX | XXX | XXX |
| EV (current) | ($31M) | XXX | ($31M) | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 0.3x | XXX | XXX | XXX |
| EV/EBIT | 0.3x | XXX | 0.2x | XXX | XXX | XXX |
| P/E | (1.8x) | XXX | (1.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 0.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Nkarta Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Nkarta Margins & Growth Rates
Nkarta's revenue in the last fiscal year grew by —.
Nkarta's revenue per employee in the last FY averaged $0.0M.
Nkarta Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (5%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Nkarta Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| CHO Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Karyopharm Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Savior Lifetec | XXX | XXX | XXX | XXX | XXX | XXX |
| PhotoCure | XXX | XXX | XXX | XXX | XXX | XXX |
| Sagimet Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nkarta M&A Activity
Nkarta acquired XXX companies to date.
Last acquisition by Nkarta was on XXXXXXXX, XXXXX. Nkarta acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Nkarta
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNkarta Investment Activity
Nkarta invested in XXX companies to date.
Nkarta made its latest investment on XXXXXXXX, XXXXX. Nkarta invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Nkarta
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Nkarta
| When was Nkarta founded? | Nkarta was founded in 2015. |
| Where is Nkarta headquartered? | Nkarta is headquartered in United States. |
| How many employees does Nkarta have? | As of today, Nkarta has over 157 employees. |
| Who is the CEO of Nkarta? | Nkarta's CEO is Paul J. Hastings. |
| Is Nkarta publicly listed? | Yes, Nkarta is a public company listed on Nasdaq. |
| What is the stock symbol of Nkarta? | Nkarta trades under NKTX ticker. |
| When did Nkarta go public? | Nkarta went public in 2020. |
| Who are competitors of Nkarta? | Nkarta main competitors are CHO Pharma, Karyopharm Therapeutics, Savior Lifetec, PhotoCure. |
| What is the current market cap of Nkarta? | Nkarta's current market cap is $175M. |
| Is Nkarta profitable? | No, Nkarta is not profitable. |
| What is the current net income of Nkarta? | Nkarta's last 12 months net income is ($99M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.